Search for Clinical Trial Results

Sponsored By

Osteomalacia - 32 Studies Found

Status Study
Recruiting Study Name: 68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia
Condition:
  • Oncogenic Osteomalacia
  • Mesenchymal Tumor

Date: 2012-01-29
Interventions: Drug: 68Ga-DOTATATE Intravenous injection of one dosage of 72-185MBq (2-5 mCi) 68Ga-DOTATATE solution. T
Recruiting Study Name: Molecular Pathways Involved in the Pathogenesis and Behavior of Mesenchymal Phosphaturic Tumors Causing Oncogenic Osteomalacia
Condition: Tumor Induced Oncogenic Osteomalacia
Date: 2015-01-05
Active, not recruiting Study Name: A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome
Condition: Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome
Date: 2016-03-07
Interventions: Drug: KRN23 Doses may be titrated to achieve the target peak serum phosphorus range
Active, not recruiting Study Name: Study of KRN23 in Adult Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)
Condition:
  • Tumor Induced Osteomalacia (TIO)
  • Epidermal Nevus Syndrome (ENS)
    Date: 2014-11-24
    Interventions: Drug: KRN23 KRN23 is a recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that b
Recruiting Study Name: Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia
Condition: Hypophosphatemia
Date: 2012-08-05
Completed Study Name: Catheterization to Locate Mesenchymal Tumors in Patients With Tumor-Induced Osteomalacia or Oncogenic Osteomalacia
Condition:
  • Osteomalacia
  • Neoplasms

Date: 2004-12-17
Terminated Study Name: Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets)
Condition: Osteomalacia
Date: 2012-12-11
Interventions: Drug: Osteomalacia
Recruiting Study Name: 68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia
Condition:
  • Oncogenic Osteomalacia
  • Mesenchymal Tumor

Date: 2012-01-29
Interventions: Drug: 68Ga-DOTATATE Intravenous injection of one dosage of 72-185MBq (2-5 mCi) 68Ga-DOTATATE solution. T
Completed Study Name: A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia
Condition: X-linked Hypophosphatemic Rickets/Osteomalacia
Date: 2014-07-02
Interventions: Drug: KRN23 Single SC administration on day 1: 0.3, 0.6 and 1.0 mg/kg
Active, not recruiting Study Name: A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome
Condition: Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome
Date: 2016-03-07
Interventions: Drug: KRN23 Doses may be titrated to achieve the target peak serum phosphorus range
Next >>>